FDA grants Jardiance breakthrough therapy designation for heart failure with preserved ejection fraction

Eli Lilly

9 September 2021 - Designation is based on results from the EMPEROR-Preserved Phase 3 trial, which established Jardiance as the first therapy to show statistically significant improvement in heart failure outcomes in adults with heart failure with preserved ejection fraction.

The U.S. FDA granted Breakthrough Therapy designation for Jardiance (empagliflozin) as an investigational treatment for adults with heart failure with preserved ejection fraction, Boehringer Ingelheim and Eli Lilly and Company announced today.

Read Eli Lilly press release

Michael Wonder

Posted by:

Michael Wonder